TrialsgrambetaRCTs are beautiful

ARISTOTLE

2011

Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF

In 18,201 patients with AF and ≥ 1 stroke risk factor, apixaban reduced stroke or systemic embolism, major bleeding and all-cause mortality compared with warfarin.

Result

Primary endpoint: Stroke or systemic embolism

1.27 %/yr vs 1.60 %/yr. Major bleed 2.13 % vs 3.09 %.

Original publication
Subtopic
Anticoagulation
Design
Double-blind, double-dummy RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Granger CB, et al. N Engl J Med. 2011;365(11):981-992.doi 10.1056/NEJMoa1107039

Discussion & critique

Apixaban is the only NOAC superior on all three: stroke, bleed, mortality. Dose-reduction criteria (age ≥ 80, weight ≤ 60 kg, Cr ≥ 1.5) are often misapplied in practice.